{"nctId":"NCT01191450","briefTitle":"Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension","startDateStruct":{"date":"2011-08"},"conditions":["Arterial Hypertension"],"count":246,"armGroups":[{"label":"Higroton®","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Higroton® Laboratório Novartis"]},{"label":"Diupress®","type":"EXPERIMENTAL","interventionNames":["Drug: Chlorthalidone 25 mg + amiloride hydrochloride 5 mg"]}],"interventions":[{"name":"Chlorthalidone 25 mg + amiloride hydrochloride 5 mg","otherNames":["Diupress® (Eurofarma Laboratórios Ltda.)"]},{"name":"Higroton® Laboratório Novartis","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Systolic blood pressure between 140 mmHg - 159 mmHg\n* Diastolic blood pressure between 90 mmHg - 99 mmHg\n* Subject aged ≥ 60 years old\n* Be able to comply with instructions, attend study follow-up visits and be willing to participate in the research project.\n* Diagnosis of stage 1 arterial hypertension with no prior treatment more than 120 days or uncontrolled during antihypertensive agent administration.\n\nExclusion Criteria:\n\n* Any serious or severe clinically significant medical condition.\n* Psychiatric or neurological diseases\n* A condition that, as per Principal Investigator's opinion, may interfere with the optimal participation in the study, or that may result in special risk to the patient.\n* Participation in any other investigational study within 12 months prior to Visit 1.\n* Known medical history of allergy, hypersensitivity or intolerance to any of the formulation compounds to be used in this study\n* Routine prior use of diuretics\n* Oral anticoagulant use\n* Fast glycemia \\> 150 mg/dL\n* Medical treatment, not related to study, scheduled for the clinical trial duration; except non-serious, controlled comorbidities in current medical follow-up.\n* Expected onset of additional antihypertensive drug after the study onset\n* Acute myocardial infarction within last 6 months\n* Prior decompensated coronary artery disease\n* Known thyroid, renal or liver dysfunction, at investigator's discretion\n* Obesity - body mass index (BMI) \\> 33 kg/m2","healthyVolunteers":false,"sex":"ALL","minimumAge":"60 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Serum Potassium Levels Below 4.0 mEq/l at Visit 4","description":"V0 (baseline) V1 (15 ± 3 days after V0) V2 (30 ± 3 days after V0) V3 (60 ± 3 days after V0) V4 (90 ± 3 days after V0)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Blood Pressure","description":"Will be considered as secondary outcomes BP \\<140 X 90 mmHg after Visit 4 (75 ± 3 days of V1).\n\nV0 (baseline) V1 (15 ± 3 days after V0) V2 (30 ± 3 days after V0) V3 (60 ± 3 days after V0) V4 (90 ± 3 days after V0)","paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"130.52","spread":"15.70"},{"groupId":"OG001","value":"131.06","spread":"13.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120.64","spread":"11.73"},{"groupId":"OG001","value":"124.05","spread":"13.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.63","spread":"10.46"},{"groupId":"OG001","value":"79.08","spread":"9.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.63","spread":"8.73"},{"groupId":"OG001","value":"75.24","spread":"9.68"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":121},"commonTop":["Metabolism and Nutrition Disorders","Investigations","Vascular Disorders","General Disorders and Administration Site Conditions","Gastrointestinal Disorders"]}}}